CTRL+Z ORAL ANTICOAGULANTS

Allen Tran, MD, FRCPC

Blood Matters 2018

Disclosures

- Speaker honorarium from Pfizer
- Subinvestigator for NASH trials involving Genfit, Novo Nordisk, and Shire

Objectives

Have an organized approach to a patient on oral anticoagulants who is bleeding

Know indications for the use of reversal agents for oral anticoagulants

Acknowledge the role of the time from last dose of anticoagulant and laboratory levels

List which pharmacologic reversal agents can be considered for each oral anticoagulant

Cases

Agnelli G, et al. N Engl J Med. 2013.
Granger CB, et al. N Engl J Med. 2011.
Connolly SJ, et al. N Engl J Med. 2009.
Schulman S, et al. N Engl J Med. 2009.
Giugliano RP, et al. N Engl J Med. 2013.
EINSTEIN Investigators. N Engl J Med. 2010.
Patel MR, et al. N Engl J Med. 2011.
HOKSUAI Investigators. N Engl J Med. 2013.
Swinkels BM, et al. Netherlands Hear J. 2015;23:111–5.
Serebruany VL, et al.Am J Hematol. 2004;75:40–7.
N Engl J Med. 1994;330:507–9.
Mauri L, et al. N Engl J Med. 2014.

Bleeding rates

	ICH	GI	Major	CRNMB
AF	0.33 - 0.8%	0.76 - 3.15%	2.13 – 3.6%	4.07 - 11.8%
VTE	0 - 0.3%	0.3 - 4.2%	0.8 - 1.9%	3.8 - 8.9%
Mechanical valve	0.6 - 0.7%		3 - 4.7%	
SAPT	0.1%	0.3 - 0.7%	1.7 - 2.7%	
DAPT	0.1 - 0.2%	0.7 - 1.3%	2.6 - 3.7%	

Agnelli G, et al. N Engl J Med. 2013.
Granger CB, et al. N Engl J Med. 2011.
Connolly SJ, et al. N Engl J Med. 2009.
Schulman S, et al. N Engl J Med. 2009.
Giugliano RP, et al. N Engl J Med. 2013.
EINSTEIN Investigators. N Engl J Med. 2010.
Patel MR, et al. N Engl J Med. 2011.
HOKSUAI Investigators. N Engl J Med. 2013.
Swinkels BM, et al. Netherlands Hear J. 2015;23:111–5.
Serebruany VL, et al.Am J Hematol. 2004;75:40–7.
N Engl J Med. 1994;330:507–9.
Mauri L, et al. N Engl J Med. 2014.

Bleeding rates

	ICH	GI	Major	CRNMB
AF	0.33 - 0.8%	0.76 - 3.15%	2.13 – 3.6%	4.07 - 11.8%
VTE	0 - 0.3%	0.3 - 4.2%	0.8 - 1.9%	3.8 - 8.9%
Mechanical valve	0.6 - 0.7%		3 - 4.7%	
SAPT	0.1%	0.3 - 0.7%	1.7 - 2.7%	
DAPT	0.1 - 0.2%	0.7 - 1.3%	2.6 - 3.7%	

Agnelli G, et al. N Engl J Med. 2013.
Granger CB, et al. N Engl J Med. 2011.
Connolly SJ, et al. N Engl J Med. 2009.
Schulman S, et al. N Engl J Med. 2009.
Giugliano RP, et al. N Engl J Med. 2013.
EINSTEIN Investigators. N Engl J Med. 2010.
Patel MR, et al. N Engl J Med. 2011.
HOKSUAI Investigators. N Engl J Med. 2013.
Swinkels BM, et al. Netherlands Hear J. 2015;23:111–5.
Serebruany VL, et al.Am J Hematol. 2004;75:40–7.
N Engl J Med. 1994;330:507–9.
Mauri L, et al. N Engl J Med. 2014.

Bleeding rates

	ICH	GI	Major	CRNMB
AF	0.33 - 0.8%	0.76 - 3.15%	2.13 – 3.6%	4.07 - 11.8%
VTE	0 - 0.3%	0.3 - 4.2%	0.8 - 1.9%	3.8 - 8.9%
Mechanical valve	0.6 - 0.7%		3 - 4.7%	
SAPT	0.1%	0.3 - 0.7%	1.7 - 2.7%	
DAPT	0.1 - 0.2%	0.7 - 1.3%	2.6 - 3.7%	

Agnelli G, et al. N Engl J Med. 2013.
Granger CB, et al. N Engl J Med. 2011.
Connolly SJ, et al. N Engl J Med. 2009.
Schulman S, et al. N Engl J Med. 2009.
Giugliano RP, et al. N Engl J Med. 2013.
EINSTEIN Investigators. N Engl J Med. 2010.
Patel MR, et al. N Engl J Med. 2011.
HOKSUAI Investigators. N Engl J Med. 2013.
Swinkels BM, et al. Netherlands Hear J. 2015;23:111–5.
Serebruany VL, et al.Am J Hematol. 2004;75:40–7.
N Engl J Med. 1994;330:507–9.
Mauri L, et al. N Engl J Med. 2014.

Bleeding rates

	ICH	GI	Major	CRNMB
AF	0.33 - 0.8%	0.76 - 3.15%	2.13 – 3.6%	4.07 - 11.8%
VTE	0 - 0.3%	0.3 - 4.2%	0.8 - 1.9%	3.8 - 8.9%
Mechanical valve	0.6 - 0.7%		3 - 4.7%	
SAPT	0.1%	0.3 - 0.7%	1.7 - 2.7%	
DAPT	0.1 - 0.2%	0.7 - 1.3%	2.6 - 3.7%	

Shih AW, Crowther MA. ASH Educ Progr B. 2016;2016:612–9.

HASHTI

Hold the drug	
Antidote consideration	•-Timing of last dose and creatinine •-Activated charcoal?
Supportive treatment for hemodynamics	
Hemostasis	Local +/- pharmacologic (antifibrinolytics or DDAVP)
Transfusion (PRBCs and/or platelets)	
Investigate for cause	

LAB TESTS

Lab tests

- Therapeutic range?
- Warfarin
  - INR
- Dabigatran
  - Normal APTT ≠ non-therapeutic levels
  - Elevated APTT = dabigatran probably present
  - Normal thrombin time (TT) = no dabigatran
  - Dilute TT with dabigatran calibrator strongly correlates with dabigatran levels
- Xa inhibitors
  - Anti-Xa activity calibrated to specific agent correlates with plasma concentration
  - Negative anti-Xa level (uncalibrated) = no Xa inhibitor
  - Normal PT ≠ non-therapeutic levels

Douxfils J, et al. J Thromb Haemost. 2017;:209–19.
Samuelson BT, et al. Chest. 2017;151:127–38.

Table 2. Pharmacokinetic properties of DOACs

		Factor Xa inhibitor		
	Direct thrombin inhibitor dabigatran	**Rivaroxaban**	**Apixaban**	**Edoxaban**
Time to peak onset	22 min-4.5 h	1-3 h	1-2 h	Unknown
Half-life	12-14 h >24 h if CrCl is <30 mL/min	5-9 h 9-13 h if patient is elderly	8-15 h	10-14 h
Drug interactions	P-gP	CYP3A4, CYP3A5, CYP2J2, P-gP	CYP3A4,P-gP	P-gP
Renal excretion (%)	80	33	25	35

CrCL, creatinine clearance.

PHARMACOKINETICS

Shih AW, Crowther MA. ASH Educ Progr B. 2016;2016:612–9.

REVERSING



Indications and Risks

Indications:

- Emergent/urgent surgery
- Life-threatening or major bleed

Risks:

- Thrombosis
- Allergic reactions
- Antibody formation

WARFARIN

Warfarin reversal: 4F PCC vs FFP

Hemostasis



Goldsten JN, et al. Lancet. 2015;385:2077–87.
Sarode R, et al. Circulation. 2013;128:1234–43.

Warfarin reversal: 4F PCC vs FFP

Infusion to procedure



Goldsten JN, et al. Lancet. 2015;385:2077–87.
Sarode R, et al. Circulation. 2013;128:1234–43.

Warfarin reversal: 4F PCC vs FFP

INR reduction by 30 min



Goldsten JN, et al. Lancet. 2015;385:2077–87.
Sarode R, et al. Circulation. 2013;128:1234–43.

Warfarin reversal: 4F PCC vs FFP

Adverse events



Goldsten JN, et al. Lancet. 2015;385:2077–87.
Sarode R, et al. Circulation. 2013;128:1234–43.

Warfarin reversal: Agents

- Immediate reversal
  - PCC + vitamin K
  - FFP only if PCC not available or history of HIT
    - + vitamin K
- Reversal within 12 – 24 hours
  - Vitamin K

PCC

- Study dosing:
  - INR 2 - 4 → PCC 25 units/kg
  - INR 4 - 6 → PCC 35 units/kg
  - INR > 6 → PCC 50 units/kg
  - Cap at 100 kg
- NAC suggested dosing:
  - INR < 3 → 1000 units
  - INR 3 – 5 → 2000 units
  - INR > 5 → 3000 units

FFP

- INR 2 - 4 → FFP 10 mL/kg
- INR 4 - 6 → FFP 12 mL/kg
- INR > 6 → FFP 15 mL/kg
- Cap at 100 kg

DOAC Reversal Trials

- Cohort design
- Laboratory endpoints
- “Effective hemostasis”

DABIGATRAN

RE-VERSE AD: Design

- 503 patients
- Group A = Major bleeding requiring reversal
- Group B = Invasive surgery/procedure needed within 8 hours
- 2.5 g IV idarucizumab x 2 (no more than 15 min apart)
  - Could get another 5 g if needed
- Primary endpoint – maximum amount of reversal from end of 1st dose to 4 hours after 2nd dose
- Secondary endpoint of hemostasis judged by treating clinician

Pollack C V, et al. N Engl J Med. 2017

RE-VERSE AD: Population

301 in Group A

45.5% GI bleed

32.6% ICH

25.9% trauma

202 in Group B

Median time from drug to procedure was 1.6 hours

78 years old

75 kg

82% white

AF in 95%

91.7% with high ECT

Analysis only included these patients

RE-VERSE AD:
Efficacy



RE-VERSE AD:
Efficacy



RE-VERSE AD:
Efficacy





Dabigatran

- Immediate
  - Idarucizumab 2.5 g IV x 2 within 15 minutes
- Non-immediate
  - Based on CrCl and drug interactions
  - 1 - 5 days of holding

XA INHIBITORS

ANNEXA: Design

- Decoy protein
- Ongoing cohort study
- Apixaban, rivaroxaban, edoxaban, or enoxaparin (therapeutic dose) taken within the last 18 hours
- Included patients with severe bleeding
- Andexanet bolus for 15 - 30 min, then 2 hour infusion
- Co-primary endpoints
  - Percent change in anti-factor Xa activity
  - Rate of excellent or good hemostasis at 12 hours after infusion

Connolly SJ, et al. N Engl J Med. 2016;375:1131–41.

ANNEXA: Population

67 patients at interim analysis

47 had elevated Xa levels

77 years old

81% white

BMI 28

4.8 hours to bolus

AF in 70%

Enoxa = 4 patients

ANNEXA:
Efficacy



ANNEXA: Efficacy



ANNEXA:
Efficacy



ANNEXA:
Efficacy

ANNEXA:
Safety

All Xa

- Immediate
  - Andexanet alfa in the US for apixaban and rivaroxaban – FDA approved
  - Health Canada has not approved any agent
- Non-immediate
  - Waiting 24 - 48 hours

Cost

EXPERIMENTAL TREATMENTS FOR DOAC REVERSAL

aPCC

14 patients on dabigatran and bleeding

- Moderate to good hemostasis with no poor hemostasis
- No TE and 1 death

No studies with Xa inhibitors in bleeding patients

- Partially corrects anti-Xa in healthy patients

PCC and bleeding time

Improved with edoxaban

Not with rivaroxaban

PCC and Riva/Apix

84 patient cohort study

69.1% effective hemostasis rate

- ICH – 38% effective hemostasis
- 2 strokes (day 5 and 10) and 1 possible PE (day 15)
- 18% died within 1 week

Experimental

Majeed A, et al. Blood. 2017.
Schulman S, et al. Thromb Res. 2017.
Shaw JR and Siegal DM. Res Pr Thromb Haemost. 2018;2 January:251–65.

Tornkvist M, et al. Thromb Res. 2018;162 December 2017:22–31.
Burnett A, et al. BMJ. 2017;357:1–8.
Almegren M. Vasc Health Risk Manag. 2017;13:287–92.

Adjuncts

- DDAVP and TXA
  - Have not been studied in DOAC-related bleeding

Universal

- Ciraparantag/PER977
  - Binds to all anticoagulants by charge interaction
  - Used in healthy volunteers and lab endpoints
  - Improved whole blood clotting time within 10 minutes on edoxaban and LMWH
  - Up to 24 hours after a single dose
  - No thrombotic events
  - Phase III clinical trial with edoxaban is ongoing

Hu TY, et al. Vasc Health Risk Manag. 2016.
Ansell JE, et al. N Engl J Med. 2014;371:2141–2.
Ansell JE, et al. Thromb Haemost. 2017.
Ansell JE, et al. Thromb Res. 2016.

SOURCE CONTROL

Case resolution





Summary

HASHTI

Timing of last dose, indication for reversal, and urgency

Idarucizumab for dabigatran

PCC and vitamin K for warfarin

Andexanet alfa soon for Xa inhibitors but costly

References

- 1. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013.
- 2. Al-Majzoub O, Rybak E, Reardon DP, Krause P, Connors JM. Evaluation of Warfarin Reversal with 4-Factor Prothrombin Complex Concentrate Compared to 3-Factor Prothrombin Complex Concentrate at a Tertiary Academic Medical Center. J Emerg Med. 2016.
- 3. Ansell JE, Bakhru SH, Laulicht BE, Steiner SS, Grosso MA, Brown K, et al. Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban. Thromb Haemost. 2017.
- 4. Ansell JE, Laulicht BE, Bakhru SH, Hoffman M, Steiner SS, Costin JC. Ciraparantag safely and completely reverses the anticoagulant effects of low molecular weight heparin. Thromb Res. 2016.
- 5. Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, et al. Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. N Engl J Med. 2015.
- 6. Connolly SJ, Milling TJ, Eikelboom JW, Gibson CM, Curnutte JT, Gold A, et al. Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. N Engl J Med. 2016.
- 7. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009.
- 8. Giugliano RP, Ruff CT, Braunwald E, Murphy S a, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013.
- 9. Granger CB, Alexander JH, McMurray JJ V, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011.
- 10. Hu TY, Vaidya VR, Asirvatham SJ. Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab. Vasc Health Risk Manag. 2016.
- 11. Investigators* TE. Oral Rivaroxaban for Symptomatic Venous Thromboembolism — NEJM. N Engl J Med. 2010.
- 12. Investigators TH-V. Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism. N Engl J Med. 2013.
- 13. Jones GM, Erdman MJ, Smetana KS, Mohrien KM, Vandigo JE, Elijovich L. 3-Factor Versus 4-Factor Prothrombin Complex Concentrate for Warfarin Reversal in Severe Bleeding: A Multicenter, Retrospective, Propensity-Matched Pilot Study. J Thromb Thrombolysis. 2016.
- 14. Majeed A, Ågren A, Holmström M, Bruzelius M, Chaireti R, Odeberg J, et al. Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: A cohort study. Blood. 2017.
- 15. Makaryus JN, Halperin JL, Lau JF. Oral anticoagulants in the management of venous thromboembolism. Nature Reviews Cardiology. 2013.
- 16. Mangram A, Oguntodu OF, Dzandu JK, Hollingworth AK, Hall S, Cung C, et al. Is there a difference in efficacy, safety, and cost-effectiveness between 3-factor and 4-factor prothrombin complex concentrates among trauma patients on oral anticoagulants? J Crit Care. 2016.
- 17. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, et al. Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents. N Engl J Med. 2014.
- 18. Murthy SB, Gupta A, Merkler AE, Navi BB, Mandava P, Iadecola C, et al. Restarting Anticoagulant Therapy after Intracranial Hemorrhage: A Systematic Review and Meta-Analysis. Stroke. 2017.
- 19. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011.
- 20. Poli L, Grassi M, Zedde M, Marcheselli S, Silvestrelli G, Sessa M, et al. Anticoagulants Resumption after Warfarin-Related Intracerebral Haemorrhage: The Multicenter Study on Cerebral Hemorrhage in Italy (MUCH-Italy). Thromb Haemost. 2018.
- 21. Pollack Jr. C V, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, et al. Idarucizumab for Dabigatran Reversal. NEnglJMed. 2015.
- 22. Proietti M, Romiti GF, Romanazzi I, Farcomeni A, Staerk L, Nielsen PB, et al. Restarting oral anticoagulant therapy after major bleeding in atrial fibrillation: A systematic review and meta-analysis. Int J Cardiol. 2018.
- 23. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009.
- 24. Schulman S, Ritchie B, Nahirniak S, Gross PL, Carrier M, Majeed A, et al. Reversal of dabigatran-associated major bleeding with activated prothrombin concentrate: A prospective cohort study. Thromb Res. 2017.
- 25. Scott MJ, Veitch A, Thachil J. Reintroduction of anti-thrombotic therapy after a gastrointestinal haemorrhage: if and when? British Journal of Haematology. 2017.
- 26. Ansell JE, Bakhru SH, Laulicht BE, Steiner SS, Grosso M, Brown K, et al. Use of PER977 to Reverse the Anticoagulant Effect of Edoxaban. N Engl J Med. 2014;371:2141–2. doi:10.1056/NEJMc1411800.
- 27. Shaw JR and Siegal DM. Pharmacological reversal of the direct oral anticoagulants—A comprehensive review of the literature. Res Pr Thromb Haemost. 2018;2 January:251–65.
- 28. DeAngelo J, Jarrell D, Cosgrove R, Camamo J, Edwards C, Patanwala AE. Comparison of 3-Factor Versus 4-Factor Prothrombin Complex Concentrate With Regard to Warfarin Reversal, Blood Product Use, and Costs. Am J Ther. 2018;25:e326–32.
- 29. Holt T, Taylor S, Abraham P, Mcmillian W, Harris S, Curtis J, et al. Three- versus four-factor prothrombin complex concentrate for the reversal of warfarin-induced bleeding. Int J Crit Illn Inj Sci. 2018;8:36–40. doi:10.4103/IJCIIS.IJCIIS_40_17.
- 30. Kuroski JE, Young S. Comparison of the safety and efficacy between 3-factor and 4-factor prothrombin complex concentrates for the reversal of warfarin. Am J Emerg Med. 2017;35:871–4. doi:10.1016/j.ajem.2017.01.049.
- 31. Tornkvist M, Smith JG, Labaf A. Current evidence of oral anticoagulant reversal: A systematic review. Thromb Res. 2018;162 December 2017:22–31. doi:10.1016/j.thromres.2017.12.003.
- 32. Burnett A, Siegal D, Crowther M. Specific antidotes for bleeding associated with direct oral anticoagulants. BMJ. 2017;357:1–8.
- 33. Almegren M. Reversal of direct oral anticoagulants. Vasc Health Risk Manag. 2017;13:287–92.
- 34. Pollack C V., Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, et al. Idarucizumab for Dabigatran Reversal — Full Cohort Analysis. N Engl J Med. 2017;:NEJMoa1707278. doi:10.1056/NEJMoa1707278.
- 35. Swinkels BM, de Mol BA, Kelder JC, Vermeulen FE, Ten Berg JM. Long-term bleeding events after mechanical aortic valve replacement in patients under the age of 60. Netherlands Hear J. 2015;23:111–5.
- 36. Kuramatsu JB, Sembill JA, Gerner ST, Sprügel MI, Hagen M, Roeder SS, et al. Management of therapeutic anticoagulation in patients with intracerebral haemorrhage and mechanical heart valves. Eur Heart J. 2018;39:1709–23.
- 37. Douxfils J, Ageno W, Samama C-M, Lessire S, ten Cate H, Verhamme P, et al. Laboratory Testing In Patients Treated With Direct Oral Anticoagulants: A Practical Guide For Clinicians. J Thromb Haemost. 2017;:209–19. doi:10.1111/jth.13912.
- 38. Samuelson BT, Cuker A, Siegal DM, Crowther M, Garcia DA. Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants: A Systematic Review. Chest. 2017;151:127–38. doi:10.1016/j.chest.2016.08.1462.
- 39. Kaatz S, Bhansali H, Gibbs J, Lavender R, Mahan C, Paje D. Reversing factor Xa inhibitors – clinical utility of andexanet alfa. J Blood Med. 2017;Volume 8:141–9. doi:10.2147/JBM.S121550.
- 40. Pollack C V., Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, et al. Idarucizumab for Dabigatran Reversal — Full Cohort Analysis. N Engl J Med. 2017;:NEJMoa1707278. doi:10.1056/NEJMoa1707278.
- 41. Sarode R, Milling TJ, Refaai MA, Mangione A, Schneider A, Durn BL, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: A randomized, plasma-controlled, phase IIIb study. Circulation. 2013;128:1234–43.
- 42. Connolly SJ, Milling TJ, Eikelboom JW, Gibson CM, Curnutte JT, Gold A, et al. Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. N Engl J Med. 2016;375:1131–41. doi:10.1056/NEJMoa1607887.
- 43. Heo YA. Andexanet Alfa: First Global Approval. Drugs. 2018;78:1049–55. doi:10.1007/s40265-018-0940-4.
- 44. Goldstein JN, Refaai MA, Milling TJ, Lewis B, Goldberg-Alberts R, Hug BA, et al. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: A phase 3b, open-label, non-inferiority, randomised trial. Lancet. 2015;385:2077–87. doi:10.1016/S0140-6736(14)61685-8.
- 45. Shih AW, Crowther MA. Reversal of direct oral anticoagulants: a practical approach. ASH Educ Progr B. 2016;2016:612–9. doi:10.1182/asheducation-2016.1.612.
- 46. Serebruany VL, Malinin AI, Eisert RM, Sane DC. Risk of Bleeding Complications with Antiplatelet Agents: Meta-Analysis of 338,191 Patients Enrolled in 50 Randomized Controlled Trials. Am J Hematol. 2004;75:40–7.
- 47. Warfarin and Aspirin after Heart-Valve Replacement. N Engl J Med. 1994;330:507–9. doi:10.1056/NEJM199402173300717.